Circle Pharma's first-in-class orally bioavailable macrocyclic cyclin A/B inhibitors highlighted in poster presentations at American Association for Cancer Research Annual Meeting
Press Release Circle Pharma announced today that two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting held April 14-19, in Orlando, Florida, highlight promising pre-clinical data of its first-in-class orally bioavailable macrocyclic…
United States Matthew Oser Eli Lilly Matthew Oser At Dana Farber Cancer Institute Circle Pharma Inc Dana Farber Cancer Institute
Source: venturebeat.com